This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Byun, H.-M. Articles by Yang, A. S. Search for Related Content PubMed PubMed Citation Articles by Byun, H.-M. Articles by Yang, A. S.

Examination of IGF2 and H19 Loss of Imprinting in Bladder Cancer

¹ Division of Hematology and ² Department of Biochemistry, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California; and ³ Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland

Requests for reprints: Allen S. Yang, USC/Norris Cancer Center, 1441 Eastlake Ave., Room 6428, University of Southern California, CA 90033. Phone: 323-865-0712; E-mail: allenyan{at}usc.edu.

Loss of imprinting (LOI) is a common epigenetic event in cancer and may serve as an early biomarker in some cancers. To obtain a better understanding of LOI, we studied 41 bladder tumors and their adjacent normal bladder mucosa. We found 2/9 (22.2%) cases that displayed LOI of IGF2 and 2/16 (12.5%) that had LOI of H19, as determined by the evaluation of mRNA for biallelic expression. In addition, we examined allele-specific methylation of the differentially methylated regions (DMR) of IGF2 and H19 using a new allele-specific pyrosequencing assay. We found that DNA methylation changes were a common finding (21/30, 70%) in the DMR regions, but could not clearly link DNA methylation changes with LOI as measured by biallelic expression. LOI and allele-specific DNA methylation changes are present in bladder cancer; however, a better understanding of the biology of LOI and its relationship to DNA methylation changes is needed before its use as an epigenetic biomarker. [Cancer Res 2007;67(22):10753–8]

This article has been cited by other articles:

				E. M. Gallagher, D. M. O'Shea, P. Fitzpatrick, M. Harrison, B. Gilmartin, J. A. Watson, T. Clarke, M. O. Leonard, A. McGoldrick, M. Meehan, et al. Recurrence of Urothelial Carcinoma of the Bladder: A Role for Insulin-Like Growth Factor-II Loss of Imprinting and Cytoplasmic E-Cadherin Immunolocalization Clin. Cancer Res., November 1, 2008; 14(21): 6829 - 6838. [Abstract] [Full Text] [PDF]

				Y. Ito, T. Koessler, A. E.K. Ibrahim, S. Rai, S. L. Vowler, S. Abu-Amero, A.-L. Silva, A.-T. Maia, J. E. Huddleston, S. Uribe-Lewis, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer Hum. Mol. Genet., September 1, 2008; 17(17): 2633 - 2643. [Abstract] [Full Text] [PDF]

				V. X. Fu, J. R. Dobosy, J. A. Desotelle, N. Almassi, J. A. Ewald, R. Srinivasan, M. Berres, J. Svaren, R. Weindruch, and D. F. Jarrard Aging and Cancer-Related Loss of Insulin-like Growth Factor 2 Imprinting in the Mouse and Human Prostate Cancer Res., August 15, 2008; 68(16): 6797 - 6802. [Abstract] [Full Text] [PDF]

				E. M. Wolff, G. Liang, C. C. Cortez, Y. C. Tsai, J. E. Castelao, V. K. Cortessis, D. D. Tsao-Wei, S. Groshen, and P. A. Jones RUNX3 Methylation Reveals that Bladder Tumors Are Older in Patients with a History of Smoking Cancer Res., August 1, 2008; 68(15): 6208 - 6214. [Abstract] [Full Text] [PDF]